ARCTURUS THERAPEUTICS HOLDINGS INC (ARCT)
Health Care · mRNA therapeutics and vaccines · NASDAQ
Arcturus Therapeutics develops self-amplifying mRNA therapeutics and vaccines, with the first approved sa-mRNA COVID vaccine (KOSTAIVE) generating revenue while advancing pipeline programs for rare genetic diseases.
What ARCTURUS THERAPEUTICS HOLDINGS INC does
Arcturus Therapeutics is a messenger RNA (mRNA) medicines company focused on developing therapeutics for liver and respiratory rare genetic diseases, as well as mRNA-based vaccines for infectious diseases. The company has proprietary platform technologies including STARR (self-amplifying mRNA) for immunogenic vaccines and LUNAR (lipid-mediated delivery system) for targeting RNA to disease-relevant tissues. Its internal pipeline includes candidates for ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), while its first approved product KOSTAIVE (sa-mRNA COVID-19 vaccine) is commercialized in Japan, the EU, and the UK through partnerships.
Themes: mRNA therapeutics, rare genetic diseases, mRNA vaccines, lipid nanoparticle delivery, respiratory diseases / cystic fibrosis, metabolic disorders / OTC deficiency
Fundamentals
- Price$13.45 as of 2026-08-21 close
- Market cap$382M as of 2026-08-21
- 1-year return-23.1% 2025-08-21 close $17.48 → 2026-08-21 close $13.45
- P/En/a negative earnings
- Net margin-317.6% as of 2026-08-24
- ROE-46.5% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)-76.0% as of 2026-08-24
- Revenue CAGR (3y)-26.4% SEC XBRL
- Beta2.44 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How ARCT compares in its sector
- net profit marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRbottom 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How ARCTURUS THERAPEUTICS HOLDINGS INC looks technically
ARCTURUS THERAPEUTICS HOLDINGS INC (ARCT) is trading 81.2% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed below its 200-day average about 179 trading days ago — a "death cross", a bearish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 43, with buyers in control. Momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 90, in overbought territory (above 70). It just made a new 20-day high, its first since 2025-10-21, pushing above its recent trading range. It is 44.4% below its highest point of the past year. Trading volume is running unusually high — about 3.8× its 30-day average, a sign of heightened interest.
Trend
8
| Distance from the 200-day | it is trading 81.2% above its 200-day average, the long-term trend line — a longer-term uptrend | +81.2% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $7.07 | $7.07 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $7.42 | $7.42 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 28 calendar days ago — the swings before that are what the structure reading is measured on | 28 sessions |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 179 trading days ago — a "death cross", a bearish long-term signal | 179 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 81.2% above | +81.2% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 43, with buyers in control | 42.7 |
Momentum
3
| 14-day RSI | momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 90, in overbought territory (above 70) | 89.6 |
|---|---|---|
| Position in its 14-day range | it is trading right at the top of its 14-day range ($5.92 to $13.50) — its "stochastic" reading is 99 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 99.3 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 15 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $24.17 | $24.17 |
|---|---|---|
| From the 52-week high | it is 44.4% below its 52-week high (its highest price of the past year) | -44.4% |
| Above the 52-week low | it is 144.5% above its 52-week low (its lowest price of the past year) | +144.6% |
| Below the 52-week high | it is 44.4% below its highest point of the past year | 44.4% |
| Since a 20-day breakout | it just made a new 20-day high, its first since 2025-10-21, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day high, its first since 2025-10-21, pushing above its recent trading range | 1 session |
| All-time high | its highest closing price on record is $188.53 (set on 2013-10-04) | $188.53 |
| Given back of the 52-week move | over the past year its closes ranged ($5.53 to $23.16), and it has recovered roughly a third of its fall from last year’s high — 45% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $16.43 to $16.99. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 44.9% |
| From the all-time high | it is 92.9% below its all-time high | -92.9% |
| Nearest price level | it is trading 1.3% below a resistance level at $13.63 — a price it turned at three times since 2025-04-23, most recently on 2025-06-10. Since 2024-08-21 it has 6 such levels below the current price and 5 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +1.3% |
| All-time low | its lowest closing price on record is $4.11 (set on 2018-12-28) | $4.11 |
| Above the all-time low | it is 227.3% above its all-time low | +227.3% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 99% of the past ~6 months) | 99th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.8275 between its high and its low — about 6.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.8275 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $3.54 and $11.49 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $3.54 – $7.51 – $11.49 |
| Typical daily range (% of price) | its price moves about 6.2% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.2% |
| Stretch from the 200-day average | it is trading 7.3 daily ranges above its 200-day average price (81.2% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 7.3 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is running unusually high — about 3.8× its 30-day average, a sign of heightened interest | 3.78× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 1.9% since the prior reading | -1.9% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
2
| Since a doji | 7 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 7 sessions ago |
|---|---|---|
| Since a bullish engulfing | 3 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 3 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.3% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +1.3% |
|---|---|---|
| Open gap | it gapped 14.6% above the previous close 2 sessions ago and has not traded back through the level it left behind at 8.21 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +14.6% |
| Gap filled | a 6.2% gap up opened on 2026-07-02 has been "filled" 31 sessions ago — price traded back through the level the gap left behind, and it took 4 sessions to close | 31 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 4 sessions in a row, a +65.23% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 4 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 122.2 percentage points (the stock gained 124.5% while the market gained 2.3%) | +122.2% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 88.5 percentage points (the stock gained 91.6% while the market gained 3.1%) | +88.5% |
| vs market, 6 months | over the past 6 months this stock beat the market by 64.3 percentage points (the stock gained 75.4% while the market gained 11.1%) | +64.3% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 43.5 percentage points (the stock lost 23.1% while the market gained 20.5%) | -43.5% |
Signal agreement
2
| Bullish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, its RSI momentum gauge is overbought (a stretched reading), near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 73% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 6.0% of the share price. | +73.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 71% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $7.87 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +70.9% |
|---|---|---|
| Vs the average paid since it last reported | the price is 36% above the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $9.92 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | +35.6% |
Price levels it has turned at before
ARCT last closed at $13.45 on 2026-08-21. Since 2024-08-21 it has turned at 6 prices below its last close and 5 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $13.63 | Resistance | 1.3% above the last close | turned there three times · 2025-04-23 to 2025-06-10 |
| $12.75 | Support | 5.2% below the last close | turned there twice · 2025-03-11 to 2025-07-15 |
| $14.84 | Resistance | 10.3% above the last close | turned there twice · 2024-11-15 to 2025-06-26 |
| $15.33 | Resistance | 13.9% above the last close | turned there three times · 2025-02-04 to 2025-07-09 |
| $9.19 | Support | 31.7% below the last close | turned there twice · 2025-10-22 to 2026-04-17 |
| $8.04 | Support | 40.2% below the last close | turned there twice · 2025-04-07 to 2026-05-29 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Tested and reclaimed 200-day support · Overbought (14-day RSI above 70) · Pulled back from the 12-month high · Unusually heavy trading volume · Broke out to a new 20-day high | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.54 mean, 1=Strong Buy…5=Strong Sell) — 10 analysts
- Mean price target$20.20 range $8.00 – $40.00; median $20.00
Analyst estimates, as of 2026-08-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ARCT
- Consensus EPS estimate-$0.6704 next reporting period, as of 2026-08-17
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant reliance on the collaboration with CSL Seqirus for commercialization and revenue, including risks of contract termination or program scaling.","Historical unprofitability and dependence on capital markets or milestone payments to fund ongoing clinical development.","Risks associated with the regulatory approval process and potential for unfavorable clinical trial outcomes for pipeline candidates ARCT-810 and ARCT-032."]
What changed in the latest 10-Q
AI-assisted comparison of ARCT's 10-Q filed 2026-05-07 against the prior one filed 2025-11-12.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-07) references Form 10-K for year ended December 31, 2025 filed March 3, 2026, whereas older filing (2025-11-12) referenced Form 10-K for year ended December 31, 2024 filed March 6, 2025
- Newer filing describes company as 'messenger RNA medicines company' focused on 'liver and respiratory rare disease therapeutics' without mention of vaccines in opening, whereas older filing described company as 'commercial messenger RNA medicines company' focused on 'development of liver and respiratory rare disease therapeutics and infectious disease vaccines'
- Newer filing reports CSL Limited's $430 million accounting write-down attributable to collaboration agreement, citing declining COVID-19 disease burden and more onerous U.S. regulatory requirements (announced February 11, 2026)
- Newer filing includes detailed Business Updates section on Arcturus-owned mRNA therapeutic candidates (LUNAR-CF/ARCT-032 and LUNAR-OTC/ARCT-810) not present in older filing's comparable section
- Newer filing reports LUNAR-CF Phase 2 trial initiated dosing in December 2024 with enrollment and dosing completed for initial three cohorts, and fourth cohort began enrolling in March 2026
- Newer filing reports March 2026 Type C meeting with FDA regarding LUNAR-OTC pediatric study plans and End-of-Phase 2 meeting discussion
- Newer filing reports UK MHRA granted marketing authorization for KOSTAIVE in January 2026 under International Recognition Procedure for individuals 18 years and older
- Newer filing reports Meiji launched two-dose vial of KOSTAIVE updated for JN.1 variant XEC in August 2025 following PMDA approval
- Removed:
- Older filing's reference to form period as 'three- and nine-month periods ended September 30, 2025' removed; newer filing specifies 'three-month period ended March 31, 2026'
- Older filing's description of company as 'commercial messenger RNA medicines company' and reference to 'transition to a commercial stage company' removed from newer filing's overview
- Older filing's reference to partnering on 'COVID-19, influenza, and three other infectious diseases' changed to 'COVID-19, influenza and other infectious diseases' in newer filing
- Older filing's detailed section 'KOSTAIVE BLA Submission' describing September 5, 2025 FDA delay request and October 14, 2025 FDA requirement for additional clinical endpoint efficacy study data not present in newer filing
- Older filing's section 'Marketing Authorization Application filing of KOSTAIVE in United Kingdom' describing June 2025 submission and expected first quarter 2026 approval removed; newer filing reports January 2026 approval as completed event
- Older filing's statement 'Meiji has launched in Japan the two-dose vial of KOSTAIVE updated for the JN.1 variant XEC following receipt of approval, in August 2025' includes 'following receipt of approval' language absent from newer filing's version
- Reworded:
- Older filing: 'We are a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines' changed in newer filing to: 'We are a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics' (removed 'commercial' and 'infectious disease vaccines')
- Older filing: 'Finally, we have significant expertise' changed in newer filing to: 'We also have significant expertise' in manufacturing processes sentence
- Older filing: CSL Seqirus described as 'a part of CSL Limited and one of the world's leading' changed in newer filing to: 'a part of CSL Limited' with CSL Seqirus later described as 'one of the world's leading influenza vaccine providers'
- Older filing: 'three other infectious diseases' changed in newer filing to: 'other infectious diseases'
- Newer filing adds narrative stating CSL Limited reported write-down and provides rationale, whereas older filing contains no comparable statement about partnership valuation changes
- Notes:
- Older filing text appears truncated at end ('In connection with our collaboration with CSL Seqirus, we continue to collect d'); comparison limited to available text
- Newer filing text also appears truncated at end ('In CSL Limited's half-year results presented on February 11, 2026, CSL Li'); comparison limited to available text
- Filings cover different reporting periods (Q3 2025 for older; Q1 2026 for newer), which naturally accounts for some content differences reflecting interim developments
Risk Factors
- Added:
- Added bullet point: 'our plans and ability to develop and commercialize our product candidates' (filed 2026-05-07)
- Added bullet point: 'interactions with regulatory authorities in the United States and foreign countries, including outcomes of meetings with the FDA regarding a regulatory pathway for ARCT-810 and ARCT-032' (filed 2026-05-07)
- Added bullet point: 'the likelihood of optimizing KOSTAIVE's product presentation and formulation' (filed 2026-05-07)
- Removed:
- Removed bullet point: 'and our ability to prevail in any disputes regarding such collaboration agreements' from collaboration agreements bullet (filed 2025-11-12)
- Removed bullet point: 'continued compliance by our strategic partners and collaborators, including CSL Seqirus, under our existing collaboration agreements' (filed 2025-11-12)
- Removed phrase: 'including those related to ARCT-810, ARCT-154 and ARCT-032' and replaced with 'including those related to our therapeutics pipeline candidates ARCT-810 and ARCT-032' (filed 2026-05-07)
- Removed bullet point: 'the likelihood or timing of any regulatory approval, and the likelihood that the marketing approval of ARCT-154 in Japan will be predictive of any future marketing approvals in other countries or for other versions of our LUNAR-COV19 or other product candidates or of any commercial sales' (filed 2025-11-12)
- Removed phrase: 'interactions with regulatory authorities in the United States and foreign countries' as standalone bullet (filed 2025-11-12)
- Removed phrase: 'arbitration, investigations, inquiries, or other proceedings' from litigation bullet; changed to 'costly litigation with shareholders, former executives or others' (filed 2026-05-07)
- Reworded:
- Changed 'the continued development activities' to 'the status of development activities' for LUNAR-COV19 and LUNAR-FLU programs (filed 2026-05-07)
- Changed 'the continued development activities of the LUNAR-COV19 and LUNAR-FLU programs' to include 'and the other infectious disease programs' (filed 2026-05-07)
- Reorganized bullet order: moved 'interactions with regulatory authorities' bullet to earlier position in list (filed 2026-05-07)
- Reorganized bullet order: moved 'our plans to develop and commercialize' bullet to earlier position in list (filed 2026-05-07)
- Notes:
- Both filings appear truncated at the end; comparison limited to complete visible text
- Page number references differ between filings (Item 1A on page 20 in 2026 filing vs. page 25 in 2025 filing), but this reflects document layout changes rather than content changes in the Risk Factors section itself
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for ARCT — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
6 institutional 13F filers reported holding ARCT as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 6,261,765
- Reported value $48,340,825
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
ARCT had 7,206,773 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
ARCT had 25.4% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 16.52 days to cover at the same settlement.
- Reported short interest (shares) 7,206,773
- Short interest (% of shares outstanding) 25.4%
- Prior settlement (shares) 7,004,482
- Reported change 2.89%
- Days to cover (reported) 16.52
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Moderna (MRNA)
- BioNTech (BNTX)
- Pfizer (PFE)
- Translate Bio (Sanofi)
- CureVac (CVAC)
- Alnylam Pharmaceuticals (ALNY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ARCT vs…
ARCT ranks in…
Frequently asked questions
What does ARCTURUS THERAPEUTICS HOLDINGS INC (ARCT) do?
Arcturus Therapeutics is a messenger RNA (mRNA) medicines company focused on developing therapeutics for liver and respiratory rare genetic diseases, as well as mRNA-based vaccines for infectious diseases. The company has proprietary platform technologies including STARR (self-amplifying mRNA) for immunogenic vaccines and LUNAR (lipid-mediated delivery system) for targeting RNA to disease-relevant tissues.
What sector is ARCTURUS THERAPEUTICS HOLDINGS INC (ARCT) in?
ARCTURUS THERAPEUTICS HOLDINGS INC (ARCT) is classified in the Health Care sector. Its industry is mRNA therapeutics and vaccines. It trades on NASDAQ.
Who are ARCTURUS THERAPEUTICS HOLDINGS INC's (ARCT) competitors?
Notable peers of ARCTURUS THERAPEUTICS HOLDINGS INC (ARCT) include Moderna, BioNTech, Pfizer, Translate Bio (Sanofi) and CureVac. This peer set is informational only — not financial advice.
Is ARCTURUS THERAPEUTICS HOLDINGS INC (ARCT) overbought or oversold right now?
ARCTURUS THERAPEUTICS HOLDINGS INC (ARCT) is currently in overbought territory (its 14-day RSI is 90, above 70) (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ARCT come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.